Epstein Barr Virus

Epstein-Barr virus, frequently referred to as EBV, is a member of the herpesvirus family and one of the most common human viruses. The virus occurs worldwide, and most people become infected with EBV sometime during their lives.
Multiple Sclerosis and the Epstein Barr Virus

Epstein-Barr virus (EBV) is a herpes virus otherwise known of as human herpesvirus 4 (HHV-4). It is most well known for causing glandular fever but research shows that EBV infection is also linked to an increased risk for various autoimmune conditions including rheumatoid arthritis, dermatomyositis and multiple sclerosis.

Read More

Overview

Latest Epstein Barr Virus News and Research

Study reports SARS-CoV-2 accessory proteins downregulate MHC-I expression using distinct mechanisms

Study reports SARS-CoV-2 accessory proteins downregulate MHC-I expression using distinct mechanisms

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

Exosomes derived from γδ-T cells synergized with radiotherapy can control nasopharyngeal carcinoma

Exosomes derived from γδ-T cells synergized with radiotherapy can control nasopharyngeal carcinoma

UC Davis researchers identify a protein that keeps Kaposi's sarcoma-associated herpesvirus dormant

UC Davis researchers identify a protein that keeps Kaposi's sarcoma-associated herpesvirus dormant

NIH launches clinical study to evaluate an investigational preventative vaccine for Epstein-Barr virus

NIH launches clinical study to evaluate an investigational preventative vaccine for Epstein-Barr virus

SARS-CoV-2 variants are not evolving to escape from T cell-mediated immunity

SARS-CoV-2 variants are not evolving to escape from T cell-mediated immunity

Acute hepatitis and adenovirus infection among pediatric patients in Alabama

Acute hepatitis and adenovirus infection among pediatric patients in Alabama

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis

COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis

Experimental tool can precisely pick out interactions between immune cell and target antigen

Experimental tool can precisely pick out interactions between immune cell and target antigen

Air surveillance of SARS-CoV-2 and other respiratory pathogens

Air surveillance of SARS-CoV-2 and other respiratory pathogens

Japanese researchers discover new mechanisms of action by extracellular vesicles in lymphoma

Japanese researchers discover new mechanisms of action by extracellular vesicles in lymphoma

Study explores immune escape mutations caused by prolonged viral shedding in immunocompromised COVID-19 patient

Study explores immune escape mutations caused by prolonged viral shedding in immunocompromised COVID-19 patient

Damon Runyon Cancer Research Foundation announces newest cohort of Fellows and Breakthrough Scientists

Damon Runyon Cancer Research Foundation announces newest cohort of Fellows and Breakthrough Scientists

Study identifies a new potential pathway for developing therapeutics against Epstein-Barr virus

Study identifies a new potential pathway for developing therapeutics against Epstein-Barr virus

Study provides insights into how SARS-CoV-2 impacts the brain

Study provides insights into how SARS-CoV-2 impacts the brain

Multiple sclerosis may be caused by infection with the Epstein-Barr virus

Multiple sclerosis may be caused by infection with the Epstein-Barr virus

SARS-CoV-2 Delta binds more strongly to furin protease than other existing variants

SARS-CoV-2 Delta binds more strongly to furin protease than other existing variants

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer